Chemoimmunotherapy for melanoma with DTIC, ACNU, VCR and OK432: evaluation of new combinations for survival rates, side effects and cellular immunity.
D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007167:Immunotherapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D010844:Picibanil / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use*
D001688:Biological Products; D009607:Nitrosourea Compounds; D015376:Nimustine; D010844:Picibanil; D014750:Vincristine; D003606:Dacarbazine